Click here to listen to this article Share via Key Facts The Rule of 20-30%: In typical weight loss, approximately 20-30% of mass lost is lean tissue (muscle/bone/water), not just fat
The mean follow-up on-treatment was 181 days (median 155 days, IQR 71 to 290 days) for tirzepatide initiators and 174 days (median 148 days, IQR 82 to 254 days) for semaglutide initiators
Semaglutide medications support weight loss by mimicking GLP-1, a hormone your body naturally releases after eating
Some GLP-1 medications, such as semaglutide, act through a single receptor, whereas tirzepatide also acts through GIP
Combining mono- and/or dual-agonists to achieve triple agonism may allow for personalisation of treatment, aiming to find the optimal balance of receptor agonism for a specific individual